Q3 2025 Viatris Inc Earnings Call Transcript
Key Points
- Viatris Inc (VTRS) delivered strong commercial performance across Europe, emerging markets, and Greater China, contributing to a 1% operational revenue growth.
- The company raised its full-year guidance for key financial metrics, including total revenues, adjusted EBITDA, and adjusted EPS, driven by strong operational performance and favorable foreign exchange impacts.
- Viatris Inc (VTRS) is advancing its R&D pipeline with promising developments, including the fast-acting meloxicam for acute pain and low-dose estrogen patches under FDA review.
- The company has returned over $920 million to shareholders year-to-date, including $500 million in share repurchases, and is on track to return over $1 billion for the year.
- Viatris Inc (VTRS) is actively pursuing business development and M&A opportunities to enhance growth, including the acquisition of Aculus Farm in Japan, which adds innovative CNS assets to its portfolio.
- Total revenues for the third quarter were down approximately 1% compared to the prior year, primarily due to the impact of the indoor facility issues.
- The North America business saw a 12% decrease in net sales versus the prior year, driven by the indoor impact and competition on certain generic products.
- Net sales in Japan decreased by approximately 9%, affected by government price regulations and changes in reimbursement policy impacting off-patent brands.
- The company faces potential challenges with competitive dynamics in North America and the potential loss of exclusivity for Amitiza in Japan.
- The timing of the FDA reinspection of the indoor facility remains uncertain, which could impact future operations and revenue recovery.
(audio in progress) -- '25 earnings call.
With us today is our CEO Scott Smith.
CFO Doretta Mistress, Chief R&D Officer Philippe Martin, and Chief Commercial Officer Cri O'Goff.
During today's call, we will be making forward-looking statements on a number of matters, including our financial guidance for 2025 and various strategic initiatives. These statements are subject to risk and uncertainties.
We will also be referring to certain actual and projected non-GAAP financial measures. Please refer to today's slide presentation and our SEC filings for more information, including reconciliations of those non-GAAP measures to the most directly comparable GAAP measures.
When discussing 2025 actual or reported results, we will be making certain comparisons to 2024 actual or reported results on a divestiture adjusted operational basis, which excludes the impact of foreign currency rates and also excludes the proportionate results from the divestitures that closed in 2024 from the 2024 period.
We may refer to those as changes
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
